Clinically Proven to Work

BELVIQ® can help you lose weight and improve certain health risk factors — In FDA clinical trials, people who added BELVIQ® to diet and exercise were able to lose weight and improve health risk factors, such as high blood pressure, high blood sugar, and high cholesterol levels. BELVIQ® was tested in two major clinical studies, one lasting a year (4,008 people) and one lasting 2 years (3,182 people).*

The combined results of these two studies showed that:

  • Almost half of people (47.1%) taking BELVIQ® lost 5% or more of their body weight after 1 year of treatment, compared with those using diet and exercise alone (22.6%)
  • Some (22.4%) lost as much as 10% of their body weight after 1 year of treatment, compared with those using diet and exercise alone (8.7%)

People taking BELVIQ with diet and exercise had significant improvements in their blood pressure and cholesterol levels, compared to those using diet and exercise alone. It is not known if BELVIQ changes your risk of heart problems, stroke, or death due to heart problems or stroke.

BELVIQ® can help you manage your weight loss — In a major clinical trial, people taking BELVIQ were able to lose weight and maintain weight loss up to 2 years. In the 2-year study, almost half of people who completed the first year continued on in year 2. All people regained weight but remained below their starting weight.

BELVIQ® helps overweight people with type 2 diabetes lose weight — BELVIQ was also tested in a study involving 604* overweight men and women with type 2 diabetes. Results showed that more than a third of people taking BELVIQ with diet and exercise (37.5%) lost 5% or more of their body weight, compared with those using diet and exercise alone (16.1%). In the same study, the BELVIQ group showed significant improvements in blood sugar levels, compared with those using diet and exercise alone.

*Nearly half of all participants completed the studies in overweight patients without diabetes; nearly two-thirds of the participants completed the study in overweight patients with diabetes.

You are leaving BELVIQ.com.

Eisai Inc. does not endorse and is not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

Continue
Cancel or close this window to return to BELVIQ.com.